Moderna Appoints New Chief Commercial Officer; Verge Labs Unveils AI Model for Clinical Trials
Moderna has announced the appointment of Ester Banque as its new Chief Commercial Officer. Banque previously served as the President of U.S. operations for Zoetis. Concurrently, Stephen Hoge, Moderna's President, will assume an expanded role, overseeing several of the company's drug development programs. In related biotech news, Verge Labs has launched a new AI model designed to enhance clinical trial enrollment by identifying patients more likely to respond to treatment, aiming to reduce dropout rates and increase statistical power.
Moderna has appointed Ester Banque as its new Chief Commercial Officer. Banque previously held the position of President of U.S. operations for Zoetis. This appointment places her in a key leadership role within Moderna's commercial strategy division.
In a concurrent development at Moderna, Stephen Hoge, the company's President, has been given an expanded set of responsibilities. He will now oversee several of Moderna's drug development programs, broadening his influence over the company's pipeline.
Separately, biotech firm Verge Labs has introduced a new artificial intelligence (AI) model. This model is specifically engineered to improve various aspects of clinical trials.
The AI model aims to assist in determining which patients are more likely to respond effectively to specific treatments. By doing so, Verge Labs intends to decrease the number of participants who drop out of clinical trials and enhance the statistical power of these studies.
According to STAT News, these developments represent ongoing shifts in leadership and technological innovation within the pharmaceutical and biotech sectors.
